Pharma player Zydus Cadila on Saturday announced that the patent litigation relating to Allergan's Delzicol (mesalamine) has been settled.

The settlement, subject to the approval from the regulator, will open the doors for the company to market its generic version in the US market.

"As a result of the settlement, and if approved by FDA, company's US subsidiary, Zydus Pharmaceuticals (USA) Inc., will be able to market its generic version of Delzicol in the United States beginning on March 1, 2020, or earlier under certain circumstances," the company informed in a statement here.

comment COMMENT NOW